Healthcare
By
Can AstraZeneca’s $50B US Investment and Eli Lilly’s $27B Manufacturing Expansion Reshape the Future of American Biopharma?
Key Highlights Virginia Bets Big on Biopharma GrowthVirginia lawmakers have approved significant development packages to draw two of…
Can Roche’s $700M Genentech Facility Drive Its $50B US Investment Strategy and Transform Obesity Drug Manufacturing?
Key Highlights Strategic Expansion into US ManufacturingGenentech, Roche’s US subsidiary, has broken ground on a new $700M state-of-the-art…
Can IQVIA and Flagship Pioneering’s AI-Driven Alliance Unlock the Next $60B Wave of Breakthrough Biopharma?
Key Highlights AI-Powered Acceleration in Drug DevelopmentThe collaboration positions IQVIA’s Healthcare-grade AI® and data-driven analytics at the center…
How AbbVie Is Expanding Its Psychiatry Pipeline Through $1.2B Acquisition of Gilgamesh Pharmaceuticals’s Next-Gen Depression Drug?
Key Highlights The Promise of BretisilocinBretisilocin (GM-2505) is a novel, short-acting 5-HT2A receptor agonist and 5-HT releaser designed…
Will BioNTech and Pfizer’s Counterstrike Against GSK Reshape Europe’s Largest mRNA Patent War?
Key Insights GSK’s Offensive Meets Resistance GSK launched a sweeping litigation campaign in 2024, targeting BioNTech and Pfizer…
Can LB Pharmaceuticals’ $285M IPO Reignite Investor Confidence in Biotech After Months of Silence?
Key Insights IPO Breaks Market Drought LB Pharmaceuticals, a CNS-focused biotech, has defied a months-long IPO drought by…
